EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease

Elisa Martínez Campos, Paula Tellechea Aramburo, Javier Sánchez Ruiz de Gordoa, Rosa Larumbe Ilundain

Revista de Neurología · 2025

DOI: 10.31083/rn36399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista de Neurología, 2025. Verfasst von Elisa Martínez Campos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neurología, Hospital Universitario de Navarra, 31008 Pamplona, España. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Amyloid beta-Peptides, Peptide Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) are essential for the early identification of non-amnestic phenotypes. Increased levels of total tau (t-tau) and phosphorylated tau (p-tau) have been reported in atypical AD cases, although the specific pattern remains a subject of debate. This study aimed to evaluate CSF biomarker profiles in relation to clinical phenotype. Materials and Methods: A retrospective review was performed, analyzing demographic data, time to diagnosis, clinical phenotype, and core AD biomarkers (beta-amyloid peptide 1-42 (Aβ1-42), t-tau, p-tau) in CSF from patients evaluated at University Hospital in Navarra between 2019 and 2022.

Results

The study included 57 patients (54% female, mean age 67 years), of whom 41 met AD diagnostic criteria. Among these, 10 patients (25%) presented with atypical phenotypes (50% aphasic, 30% frontal, 20% mixed non-amnestic). Compared with the amnestic phenotype, the atypical group exhibited significantly higher t-tau (562.9 pg/mL vs 320.3 pg/mL, p = 0.021) and p-tau (81.5 pg/mL vs 37.7 pg/mL, p = 0.016) levels, independent of age, sex, and time to diagnosis.

Conclusions

Atypical cases demonstrated increased tau levels, suggesting earlier and more extensive cortical damage than the amnestic phenotype. These findings underscore the significance of CSF biomarkers in phenotypic differentiation, disease course prediction, and individualized treatment strategies for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsAmyloid beta-PeptidesPeptide FragmentsHumansFemaleAgedMaleBiomarkersRetrospective StudiesMiddle AgedAged, 80 and overPhenotype

Stichwörter der Autor:innen

Alzheimer-type dementia (ATD)Alzheimer’s disease, early onsetaphasia, primary progressivecerebrospinal fluidtau proteins

Substanzen

Biomarkerstau ProteinsAmyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)MAPT protein, human

Autor:innen und Institutionen

  • Servicio de Neurología, Hospital Universitario de Navarra, 31008 Pamplona, España.

Zitieren

APA

Martínez Campos, E., Tellechea Aramburo, P., Sánchez Ruiz de Gordoa, J., & Larumbe Ilundain, R. (2025). Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease. Revista de Neurología. https://doi.org/10.31083/rn36399

Vancouver

Martínez Campos E, Tellechea Aramburo P, Sánchez Ruiz de Gordoa J, Larumbe Ilundain R. Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease. Revista de Neurología. 2025. doi:10.31083/rn36399

BibTeX
@article{MartnezCampos2025,
  author = {Martínez Campos, Elisa and Tellechea Aramburo, Paula and Sánchez Ruiz de Gordoa, Javier and Larumbe Ilundain, Rosa},
  title = {Cerebrospinal Fluid Biomarker Profile in Atypical Alzheimer’s Disease},
  journal = {Revista de Neurología},
  year = {2025},
  doi = {10.31083/rn36399}
}
Kostenlos starten →